NASDAQ · TGTX
Healthcare · Biotechnology
$61.18
Up+$3.10 (+5.34%)
Updated Oct 31, 2026, 2:33 AM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance · TGTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
TGTX closed at $61.18 after 21 trading sessions, up 12.69% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $58.15 | $61.7599 | $58.00 | $61.18 | 2.86M |
| Oct 29, 2026 | $57.81 | $58.96 | $56.93 | $58.08 | 1.79M |
| Oct 28, 2026 | $55.84 | $57.46 | $55.66 | $57.40 | 933.76K |
| Oct 27, 2026 | $54.10 | $57.08 | $53.88 | $56.44 | 1.48M |
| Oct 26, 2026 | $54.81 | $55.49 | $53.71 | $54.79 | 1.19M |
| Oct 23, 2026 | $52.56 | $55.805 | $51.8327 | $54.17 | 1.98M |
| Oct 22, 2026 | $53.02 | $53.70 | $52.53 | $53.16 | 1.29M |
| Oct 21, 2026 | $54.51 | $54.9465 | $52.73 | $53.20 | 1.18M |
| Oct 20, 2026 | $53.36 | $55.32 | $53.08 | $54.53 | 1.06M |
| Oct 19, 2026 | $54.35 | $54.97 | $52.90 | $53.30 | 1.55M |
| Oct 16, 2026 | $56.00 | $56.245 | $53.66 | $53.97 | 1.77M |
| Oct 15, 2026 | $55.12 | $56.83 | $54.755 | $56.00 | 1.81M |
| Oct 14, 2026 | $54.08 | $55.37 | $53.36 | $54.37 | 1.29M |
| Oct 13, 2026 | $55.23 | $55.39 | $53.63 | $54.34 | 1M |
| Oct 12, 2026 | $55.38 | $55.86 | $54.65 | $55.27 | 758.15K |
| Oct 9, 2026 | $53.72 | $55.46 | $53.36 | $55.37 | 1.62M |
| Oct 8, 2026 | $53.34 | $53.90 | $52.1201 | $53.34 | 1.74M |
| Oct 7, 2026 | $51.83 | $53.88 | $51.405 | $52.95 | 1.51M |
| Oct 6, 2026 | $54.11 | $54.11 | $51.34 | $52.19 | 2.41M |
| Oct 5, 2026 | $54.35 | $54.75 | $53.321 | $53.91 | 1.55M |
| Oct 2, 2026 | $54.17 | $54.98 | $53.145 | $54.29 | 1.65M |
The latest Smart Investors Daily articles mentioning TGTX.
Company
Market Activity
Research & News
TGTX research
Company profile and research snapshot.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Jul 27, 2026 | B. Riley Securities | Buy | — |
| Jul 13, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 7, 2026 | B of A Securities | Underperform | — |
No generated briefing is available yet.
Yahoo · Oct 23, 2026
The Phase 1 trial evaluated patients whose disabilities continued to worsen despite receiving other treatments.
Yahoo · Oct 23, 2026
NEW YORK, October 23, 2026--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company’s Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational, allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with progressive multiple sclerosis (MS). The data represent the first reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS and were presented in a late-breaking oral sess
Benzinga · Oct 23, 2026
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced initial results from the Company’s Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational, allogeneic CD19-directed chimeric antigen
Yahoo · Oct 21, 2026
NEW YORK, October 21, 2026--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced several updated poster presentations at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. The presentations include seven-year follow up data from the ULTIMATE I & II trials, Phase 1 subcutaneous BRIUMVI data, Phase 3 ENHANCE trial data, an update from the ENABLE real world study, and more presentations highlighting BRIUMVI data.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TGTX.
